Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in mu...
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
About this item
Full title
Author / Creator
Polman, Chris H, Prof , Bertolotto, Antonio, MD , Deisenhammer, Florian, Prof , Giovannoni, Gavin, Prof , Hartung, Hans-Peter, Prof , Hemmer, Bernhard, Prof , Killestein, Joep, MD , McFarland, Henry F, MD , Oger, Joel, Prof , Pachner, Andrew R, Prof , Petkau, John, Prof , Reder, Anthony T, MD , Reingold, Stephen C, PhD , Schellekens, Huub, Prof and Sørensen, Per Soelberg, Prof
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy. In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy...
Alternative Titles
Full title
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
Authors, Artists and Contributors
Author / Creator
Bertolotto, Antonio, MD
Deisenhammer, Florian, Prof
Giovannoni, Gavin, Prof
Hartung, Hans-Peter, Prof
Hemmer, Bernhard, Prof
Killestein, Joep, MD
McFarland, Henry F, MD
Oger, Joel, Prof
Pachner, Andrew R, Prof
Petkau, John, Prof
Reder, Anthony T, MD
Reingold, Stephen C, PhD
Schellekens, Huub, Prof
Sørensen, Per Soelberg, Prof
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_754565193
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_754565193
Other Identifiers
ISSN
1474-4422
E-ISSN
1474-4465
DOI
10.1016/S1474-4422(10)70103-4
